Page 16 - Edwards Higher Standard Brochure PP--US-5551 v3.0
P. 16

Continuing to meet the emerging needs of new patient populations with SAPIEN 3 Ultra TAVR
     Designed for durability
Designed to facilitate future coronary access
Excellent outcomes in low-risk bicuspid patients
    PARTNER II S3i: Excellent outcomes out to 5 years with durability similar to SAVR7
The SAPIEN 3 Ultra valve allows for future coronary intervention with a low frame height and large cell design
0% death or disabling stroke and very low rates of mild or greater PVL at 30 days9
 100%
successful coronary access post-TAVR8
68/68 patients
     
























































































   14   15   16   17   18